Latham & Watkins LLP has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a European leader in well-established medicines, on a private placement of €390 million senior secured notes.
The refinancing follows Cheplapharm’s recently announced €1.2 billion term loan B financing as well as the announcement of Cheplapharm’s strategic partnership with Sanofi. Latham & Watkins advised Cheplapharm on both of these transactions.
The Latham team was led by Munich Capital Markets partner Rüdiger Malaun and Frankfurt Capital Markets partner Jan Penselin, with associates Peter Neuböck and Tobias Müller. Advice was also provided on tax matters by Munich partner Ulf Kieker.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
